Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin.
Formalin-fixed and paraffin-embedded human Lung carcinoma reacted with ACK1 Antibody , which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
Western blot of ACK1 (arrow) using rabbit polyclonal ACK1 Antibody. 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the ACK1 gene (Lane 2) (60 KD recombinant protein).
Western blot of ACK1 Antibody in K562 cell line lysates (35 ug/lane). ACK1 (arrow) was detected using the purified antibody.
Flow cytometric of NCI-H292 cells using ACK1 Antibody (bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
Requested From: United States
Date Requested: 2/20/2017